English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 848007      Online Users : 693
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/15392


    Title: In vitro and in vivo evidence discourages routine testing and reporting of piperacillin/tazobactam susceptibility of Elizabethkingia species
    Authors: Tan, MC;Huang, YC;Chen, PJ;Huang, WC;Hsu, SY;Wang, HY;Liou, CH;Sun, JR;Lauderdale, TY;Kuo, SC
    Contributors: National Institute of Infectious Diseases and Vaccinology;Institute of Population Health Sciences
    Abstract: Sir,Elizabethkingia species are increasingly prevalent pathogens, particularly in Asia, and are considered intrinsically resistant to almost all β-lactams.1 However, piperacillin/tazobactam susceptibility testing is performed frequently in clinical laboratories and reported in the literature,1 and piperacillin/tazobactam is used to treat infections caused by susceptible Elizabethkingia strains.2 Herein, we question the practice of routine testing and reporting of piperacillin/tazobactam susceptibility of Elizabethkingia spp. due to variability of broth microdilution (BMD) results read by different laboratorians, discordant results of various susceptibility assays, discrepancy between MICs versus MBC or in vivo efficacy and intrinsic resistance evidenced by knockout experiments. One-hundred and eight Elizabethkingia isolates from our previous nationwide studies (Supplementary Methods, available as Supplementary data at JAC Online)3 frequently demonstrated trailing with faint button or turbidity above 4–8 mg/L in BMD testing of piperacillin/tazobactam susceptibility, thus impeding reading (Figure S1). Trailing was also observed in BMD testing of ceftazidime but at a higher concentration (≥64 mg/L). BMD MIC results of piperacillin/tazobactam read by four experienced staff from separate microbiological laboratories varied greatly. Concordance (defined by all four results falling within a 2-fold range) was only 47.2% (51/108, Figure S2); poor concordance was observed both in Elizabethkingia anophelis (45.6%, 41/90) and other Elizabethkingia spp. (55.6%, 10/18). These results may explain the high variability of piperacillin/tazobactam susceptibility rates reported in the literature, which range from 5% to 100% even when obtained from the same BMD platform (piperacillin/tazobactam susceptibility from 5% to 92.4%).
    Date: 2024-01
    Relation: Journal of Antimicrobial Chemotherapy. 2024 Jan 3;79(1):200-202
    Link to: http://dx.doi.org/10.1093/jac/dkad322
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0305-7453&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:001085659600001
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85181588681
    Appears in Collections:[郭書辰] 期刊論文
    [楊采菱] 期刊論文
    [黃盈綺] 期刊論文
    [其他] 期刊論文

    Files in This Item:

    File Description SizeFormat
    PUB37850648.pdf256KbAdobe PDF108View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback